Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space.
Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend at 7AM PST / 10AM EST / 3PM BST / 4PM CET.
You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.
In his presentation, Darrell Green will tell a personal story about why he investigates primary bone cancer, shares why commercial kits used for small RNA NGS studies are biased and how to reduce the bias to reveal novel small RNAs, and explains why and how these new small RNAs are investigated at the molecular level, which leads to new drug development.
Panna Sharma will discuss some of the use-cases of NGS in developing oncology targets and the benefits and challenges we’re seeing in regard to the technology’s use.
NGS has transformed the genomics market from basic research to the clinic, and so Dr Budel and Dr Edwards’ presentation will focus on the pivotal role NGS plays at various developmental stages in biopharma, most notably in oncology.
This webinar will answer the following questions:
- How is NGS being used to find new drugs to treat cancer?
- Can NGS increase the chances of an oncology drug making it to market?
- Can NGS identify previously undruggable targets in cancer?
- How can the technology best be implemented in research labs?
- Will NGS help drive personalised cancer therapies?
- Can NGS technology help direct patients towards suitable clinical trials?